Payment overview · 2025
General Payments
$437.18
24 reported records · 13 companies
Healthcare provider profile · identity verified
Daniel Camarillo, MD
Allopathic & Osteopathic Physicians|Family Medicine · MENIFEE, CA · NPI 1073693552
Verified facts
What the public records show
CMS Open Payments records show Daniel Camarillo, MD received $437.18 in general payments during 2025 across 24 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Tresiba by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $103.63 | 23.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.17 | 15.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.27 | 9.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.80 | 8.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.48 | 8.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.04 | 7.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.22 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.00 | 4.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.97 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.49 | 3.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.99 | 3.7% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.54 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.58 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $437.18 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $103.63 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.17 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.17 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.80 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 59 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
78 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 863 | 291 |
| Atorvastatin Calcium | Atorvastatin Calcium | 783 | 236 |
| Levothyroxine Sodium | Levothyroxine Sodium | 693 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 613 | 179 |
| Metformin Hcl | Metformin Hcl | 450 | 136 |
| Losartan Potassium | Losartan Potassium | 429 | 134 |
| Lisinopril | Lisinopril | 389 | 117 |
| Omeprazole | Omeprazole | 328 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 78 |
| Carvedilol | Carvedilol | 265 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 87 |
| Alprazolam | Alprazolam | 239 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 70 |
| Donepezil Hcl | Donepezil Hcl | 227 | 67 |
| Irbesartan | Irbesartan | 220 | 70 |
| Alendronate Sodium | Alendronate Sodium | 218 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 68 |
| Furosemide | Furosemide | 217 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 76 |
| Gabapentin | Gabapentin | 198 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 59 |
| Ozempic | Semaglutide | 180 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 178 | 78 |
| Eliquis | Apixaban | 176 | 51 |
| Allopurinol | Allopurinol | 158 | 42 |
| Jardiance | Empagliflozin | 157 | 47 |
| Sertraline Hcl | Sertraline Hcl | 148 | 48 |
| Trazodone Hcl | Trazodone Hcl | 148 | 47 |
| Tramadol Hcl | Tramadol Hcl | 141 | 44 |
| Mounjaro | Tirzepatide | 135 | 27 |
| Simvastatin | Simvastatin | 133 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 118 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 33 |
| Famotidine | Famotidine | 113 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 29 |
| Potassium Chloride | Potassium Chloride | 103 | 38 |
| Spironolactone | Spironolactone | 98 | 36 |
| Benazepril Hcl | Benazepril Hcl | 96 | 28 |
| Ibuprofen | Ibuprofen | 96 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 57 |
| Folic Acid | Folic Acid | 87 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 82 | 24 |
| Glipizide | Glipizide | 79 | 26 |
| Chlorthalidone | Chlorthalidone | 78 | 24 |
| Metformin Hcl Er | Metformin Hcl | 78 | 23 |
| Trulicity | Dulaglutide | 78 | 11 |
| Atenolol | Atenolol | 77 | 22 |
| Entresto | Sacubitril/Valsartan | 76 | 18 |
| Ezetimibe | Ezetimibe | 76 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 17 |
| Glimepiride | Glimepiride | 71 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 24 |
| Memantine Hcl | Memantine Hcl | 64 | 20 |
| Montelukast Sodium | Montelukast Sodium | 62 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 20 |
| Synthroid | Levothyroxine Sodium | 59 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 19 |
| Finasteride | Finasteride | 58 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 23 |
| Cephalexin | Cephalexin | 57 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 22 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Cefdinir | Cefdinir | 55 | 52 |
| Fenofibrate | Fenofibrate | 54 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 17 |
| Temazepam | Temazepam | 49 | 13 |
| Meclizine Hcl | Meclizine Hcl | 48 | 34 |
| Meloxicam | Meloxicam | 48 | 15 |
| Nitroglycerin | Nitroglycerin | 48 | 35 |
| Farxiga | Dapagliflozin Propanediol | 46 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 14 |
| Methylprednisolone | Methylprednisolone | 45 | 38 |
| Lovastatin | Lovastatin | 44 | 11 |
| Celecoxib | Celecoxib | 41 | 21 |
| Clonidine Hcl | Clonidine Hcl | 41 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 13 |
| Pregabalin | Pregabalin | 40 | 11 |
| Valsartan | Valsartan | 40 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Nystatin | Nystatin | 38 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 32 |
| Clonazepam | Clonazepam | 36 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 16 |
| Mupirocin | Mupirocin | 36 | 26 |
| Sucralfate | Sucralfate | 36 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Baclofen | Baclofen | 33 | 15 |
| Ketoconazole | Ketoconazole | 32 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 12 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Fluocinonide | Fluocinonide | 28 | 19 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | 12 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Linzess | Linaclotide | 26 | 15 |
| Ondansetron Odt | Ondansetron | 25 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Wegovy | Semaglutide | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Nystop | Nystatin | 23 | suppressed |
| Diazepam | Diazepam | 22 | 12 |
| Prednisone | Prednisone | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 11 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 12 |
| Azithromycin | Azithromycin | 18 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | 11 |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Tresiba | Insulin Degludec | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $437.18 · 24 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, BREZTRI, CONTRAVE, Dexcom G6 Transmitter, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, Tlando, VENASEAL, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error